Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?

Feb 09 2004

• By The Pink Sheet

Related Content

Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?

Jan 19 2004

Aventis Plans To Launch Genasense, Ketek and Apidra In 2004

Jan 19 2004

Exubera May Be Wild Card In Sanofi Bid For Aventis; Genta Deal Unaffected

Feb 02 2004

Sanofi/Aventis Merger Would Create Top 10 U.S. Pharma Company

Feb 02 2004

Taxotere Will Benefit From “Average Sales Price” Reimbursement

Feb 09 2004

Aventis Ketek Will Return To FDA Advisory Committee Jan. 8

Nov 04 2002

Aventis Diabetes Outlook: Lantus Has Brighter Future Than Exubera, Firm Says

Oct 07 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window